Provided by Healio
November 15, 2013
WASHINGTON — Combined sofosbuvir and ribavirin therapy to treat established recurrent hepatitis C infection after liver transplant has proven successful in preliminary results, according to research presented by Michael R. Charlton, MD, in a late-breaking abstract at The Liver Meeting.
The ongoing single-arm, open-label interferon-free pilot study enrolled 40 naive and treatment-experienced patients with recurrent HCV infection of any genotype after liver transplantation. The patients received up to 24 weeks ofsofosbuvir and ribavirin with a primary endpoint of sustained virologic response 12 weeks after completion of treatment.
All patients were negative at end of treatment, and preliminary results show SVR4 in 77% of patients.
“I don’t think SVR4 is enough in this patient population, and we absolutely have to see SVR12,” Charlton, of Mayo Clinic in Rochester, Minn., said. “These are really preliminary data, but they are extremely encouraging.”
Disclosure: Charlton reports no relevant financial disclosures.
For more information:
Charlton MR. #LB-2: Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study. Presented at: The Liver Meeting 2013; Nov. 1-5, Washington.